856167-67-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-isobutylbenzonitrile is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of active pharmaceutical ingredients. Its unique chemical structure allows it to be a key component in creating a range of medications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-2-isobutylbenzonitrile is utilized as a building block in the synthesis of different agrochemicals, playing a crucial role in the production of substances that help protect and enhance crop yields.
Used in Specialty Chemicals Synthesis:
5-Bromo-2-isobutylbenzonitrile is also used as a versatile building block in the synthesis of specialty chemicals, where its chemical properties are harnessed to create a variety of compounds for specific applications across multiple industries.

Upstream product

• 121554-10-7 5-bromo-2-iodobenzonitrile 
• 288251-96-7 2-(2-methylpropyl)-5-nitrobenzonitrile 
• 288251-97-8 5-amino-2-(2-methylpropyl)benzonitrile 
• 134604-07-2 2-bromo-5-nitrobenzonitrile 

Downstream Products

• 1334608-00-2 ethyl 4-(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)butanoate 
• 1334608-10-4 5-[5-(2-ethyl-3-formylphenyl)-2-pyrimidinyl]-2-(2-methylpropyl)benzonitrile 
• 1334608-14-8 5-(5-bromo-pyrimidin-2-yl)-2-isobutyl-benzonitrile 
• 1334608-18-2 5-(5-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-2-pyrimidinyl)-2-(2-methylpropyl)benzonitrile 
• 1334608-19-3 5-{5-[2-ethyl-3-(2-oxoethyl)phenyl]-2-pyrimidinyl}-2-(2-methylpropyl)benzonitrile 
• 1334608-23-9 ethyl 4-[(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)oxy]butanoate 
• 1334606-96-0 4-(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)butanoic acid 
• 1334608-27-3 methyl N-[(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)methyl]-N-methylglycinate 
• 1334608-26-2 methyl N-[2-(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)ethyl]-N-methylglycinate 
• 1334607-77-0 4-[(3-{2-[3-cyano-4-(2-methylpropyl)phenyl]-5-pyrimidinyl}-2-ethylphenyl)oxy]butanoic acid 
• 1344998-91-9 C₃₀H₃₆N₄O₂S 
• 1344998-08-8 5-{3-[2-ethyl-3-(4-piperidinyl)phenyl]-1,2,4-thiadiazol-5-yl}-2-(2-methylpropyl)benzonitrile 
• 1344998-06-6 1,1-dimethylethyl 4-(3-{5-[3-cyano-4-(2-methylpropyl)phenyl]-1,2,4-thiadiazol-3-yl}-2-ethylphenyl)-1-piperidinecarboxylate 
• 1344997-82-5 5-[5-(2-ethyl-3-formylphenyl)-1,3-thiazol-2-yl]-2-(2-methylpropyl)benzonitrile 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

BIARYL COMPOUND, PREPARATION METHOD AND USE THEREFOR

The present invention belongs to the technical field of chemical pharmaceuticals, and relates to a compound represented by general formula (I) or formula (II) and a preparation method thereof. The compounds are biaryl derivatives with RORγt activation activity. The biaryl derivatives disclosed in this invention can effectively activate the RORγt protein receptor, and thereby promote the differentiation of Th17 cells and increasing the production of IL-17, which can be used as an immune modulator for the treatment of various cancers or viral infection-related diseases.

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as a sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

NOVEL S1P RECEPTOR MODULATING AGENT

An object of the present invention is to provide a compound having a modulating activity at an S1P receptor which is useful for preventing and treating autoimmune diseases, allergic diseases, and the like. According to the present invention, a compound re

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as sphingosine 1- phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS

Compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by S1P1 receptors.

(3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS

The present invention encompasses compounds of Formula A: A as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.